(NYSE: BDX) Becton Dickinson & Co's forecast annual revenue growth rate of 3.92% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 8.45%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.87%.
Becton Dickinson & Co's revenue in 2025 is $21,386,000,000.On average, 8 Wall Street analysts forecast BDX's revenue for 2025 to be $6,264,757,831,302, with the lowest BDX revenue forecast at $6,253,838,757,870, and the highest BDX revenue forecast at $6,276,717,362,446. On average, 8 Wall Street analysts forecast BDX's revenue for 2026 to be $6,574,919,708,527, with the lowest BDX revenue forecast at $6,520,488,292,281, and the highest BDX revenue forecast at $6,643,451,476,482.
In 2027, BDX is forecast to generate $6,877,238,884,944 in revenue, with the lowest revenue forecast at $6,781,892,544,009 and the highest revenue forecast at $6,944,696,946,401.